Biolinq, a San Diego, CA-based healthcare technology company providing precision multi-analyte biosensors, raised $100M in Series C funding.
The round was led by Alpha Wave Ventures, with participation from existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital.
The company intends to use the funds to support its transition from development stage to commercial readiness following US pivotal trial completion and regulatory submission.
Led by CEO Rich Yang, Biolinq is a healthcare technology company providing precision multi-analyte wearable sensors to improve metabolic health. Its glucose sensor patch placed on the upper forearm features a color-changing indicator light, providing users with real-time feedback to stay informed about glucose excursions. it is designed for ease of use and reliability leveraging a biosensing platform that enables future multi-analyte sensing capabilities.
FinSMEs
23/04/2025